Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 12.7%

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large decline in short interest in January. As of January 15th, there was short interest totaling 321,350 shares, a decline of 12.7% from the December 31st total of 368,262 shares. Based on an average trading volume of 383,032 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.2% of the company’s stock are short sold. Currently, 2.2% of the company’s stock are short sold. Based on an average trading volume of 383,032 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Ratings Changes

A number of analysts have recently issued reports on HOTH shares. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a research report on Thursday, December 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research note on Monday, December 22nd. Finally, Wall Street Zen downgraded shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.00.

Hoth Therapeutics Stock Performance

NASDAQ:HOTH opened at $0.80 on Thursday. The stock’s 50 day moving average price is $1.06 and its 200 day moving average price is $1.28. Hoth Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.12. The company has a market capitalization of $12.44 million, a P/E ratio of -0.76 and a beta of 0.56.

Hoth Therapeutics (NASDAQ:HOTH) last posted its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.20). As a group, sell-side analysts forecast that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

Several hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Hoth Therapeutics by 8.0% during the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after buying an additional 9,071 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Hoth Therapeutics during the 3rd quarter worth about $184,000. Citadel Advisors LLC acquired a new position in shares of Hoth Therapeutics during the 3rd quarter valued at about $232,000. Lido Advisors LLC bought a new position in shares of Hoth Therapeutics in the 3rd quarter valued at approximately $32,000. Finally, Kestra Private Wealth Services LLC bought a new position in shares of Hoth Therapeutics in the 3rd quarter valued at approximately $51,000. 7.08% of the stock is owned by institutional investors and hedge funds.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.